Monthly shot may beat daily pills for schizophrenia
NCT ID NCT07075237
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether switching from daily oral antipsychotics to a monthly injection of paliperidone palmitate helps people with schizophrenia control symptoms and improve social function. Researchers will enroll 120 adults aged 18-65 who are stable on oral meds. Participants receive injections for 6 months, and the team tracks symptom severity and daily functioning.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
paliperidone palmitate injection
What this could lead to
If successful, this could show that switching to a monthly injection helps people with schizophrenia maintain symptom control and improve social functioning better than daily pills.
What could go wrong
This is a small, early-stage Phase 4 study with only 120 participants. Results may not apply to everyone, and injections can cause side effects like injection-site reactions or movement disorders.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Brain Hospital
Nanjing, Jiangsu, 210024, China
Contact Phone: •••-•••-•••• Email: •••••@•••••